Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alnylam Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

59 comunicati stampa

Guarda tutti i comunicati
29/01/2026
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
17/12/2025
Industria
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/12/2025
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/12/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Alnylam Pharmaceuticals Announces Changes to Board of Directors
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/11/2025
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Eventi
Analisi di mercato
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Web e Social Network
Eventi
Finanza
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Cardiologia
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
16/10/2025
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0